Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 4Active not recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other solid neoplasm 1Other 1Breast 1

Conditions

Obesity 1Metabolic Syndrome 1Inflammation 1Hematopoietic and Lymphatic System Neoplasm 1Dyslipidemias 1Breast Neoplasms 1

Interventions

pembrolizumab 382Carboplatin 280Specimen Handling 266Nivolumab 256Magnetic Resonance Spectroscopy 247Cyclophosphamide 243Cisplatin 215Paclitaxel 209Radiotherapy 194Biopsy 171Gemcitabine 156Dexamethasone 149durvalumab 148atezolizumab 127Rituximab 122Doxorubicin 119Bevacizumab 115Ipilimumab 114Lenalidomide 112Radiation 111Pemetrexed 104Docetaxel 104Etoposide 103venetoclax 98fludarabine 97Capecitabine 94Radiosurgery 93Fluorouracil 93Prednisone 90Oxaliplatin 90

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Bupropion × 1 year × Clear all
NCT05646862 2026-05-06

INAVO121

Hoffmann-La Roche

Phase 3 Active not recruiting
420 enrolled
Breast

Breast Neoplasms

NCT03996265 2026-01-15

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

University of Rochester

Phase 3 Active not recruiting
422 enrolled
Other solid neoplasm

Hematopoietic and Lymphatic System Neoplasm

NCT05756764 2025-09-09

Anti-obesity Pharmacotherapy and Inflammation

Louisiana State University Health Sciences Center in New Orleans

Active not recruiting
30 enrolled
Other

Inflammation, Obesity, Metabolic Syndrome, Dyslipidemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡